BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 153] [Article Influence: 19.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhou Y, Wang Y, Zhou W, Chen T, Wu Q, Chutturghoon VK, Lin B, Geng L, Yang Z, Zhou L, Zheng S. YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell Int 2019;19:179. [PMID: 31337986 DOI: 10.1186/s12935-019-0898-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 9.7] [Reference Citation Analysis]
2 Lan X, Zhang H, Li H, Chen K, Liu F, Wei Y, Li B. Dynamic changes of portal vein pressure gradient under different degrees of liver cirrhosis and resection volume in the first week post hepatectomy: The original pathophysiologic data. Hepatol Res 2018;48:978-88. [DOI: 10.1111/hepr.13197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 van Breugel JMM, Geschwind JF, Mirpour S, Savic LJ, Zhang X, Duran R, Lin M, Miszczuk M, Liapi E, Chapiro J. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019;9:3674-86. [PMID: 31281506 DOI: 10.7150/thno.32943] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
4 Zhuang J, Song Y, Ye Y, He S, Ma X, Zhang M, Ni J, Wang J, Xia W. PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer. J Transl Med 2019;17:343. [PMID: 31619254 DOI: 10.1186/s12967-019-2091-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
5 Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L. Combinatorial immunotherapy strategies for hepatocellular carcinoma. Curr Opin Immunol 2016;39:103-13. [PMID: 26851637 DOI: 10.1016/j.coi.2016.01.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
6 Tao LP, Fan XP, Fan YC, Zhao J, Gao S, Wang K. Combined detection of insulin-like growth factor-binding protein 7 promoter methylation improves the diagnostic efficacy of AFP in hepatitis B virus-associated hepatocellular carcinoma. Pathol Res Pract 2018;214:144-50. [PMID: 29108923 DOI: 10.1016/j.prp.2017.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Han Y, Zhang L, Yu X, Wang S, Xu C, Yin H, Wang S. Alginate oligosaccharide attenuates α2,6-sialylation modification to inhibit prostate cancer cell growth via the Hippo/YAP pathway. Cell Death Dis 2019;10:374. [PMID: 31076566 DOI: 10.1038/s41419-019-1560-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
8 Wang PM, Chung NN, Hsu WC, Chang FL, Jang CJ, Scorsetti M. Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve. Rep Pract Oncol Radiother 2015;20:417-24. [PMID: 26696781 DOI: 10.1016/j.rpor.2015.03.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A. Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:5162-79. [PMID: 34410432 DOI: 10.1007/s00261-021-03248-9] [Reference Citation Analysis]
10 Liang Y, Lin C, Zhang B, Cao J, Chen M, Shen J, Feng X, Xiao G, Pan L, Chen K, Maher H, Cai X. Perioperative outcomes comparing laparoscopic with open repeat liver resection for post-hepatectomy recurrent liver cancer: A systematic review and meta-analysis. Int J Surg. 2020;79:17-28. [PMID: 32240816 DOI: 10.1016/j.ijsu.2020.03.052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
11 Aliberti C, Carandina R, Sarti D, Mulazzani L, Pizzirani E, Guadagni S, Fiorentini G. Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma. American Journal of Roentgenology 2017;209:430-4. [DOI: 10.2214/ajr.16.17477] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bird TG, Dimitropoulou P, Turner RM, Jenks SJ, Cusack P, Hey S, Blunsum A, Kelly S, Sturgeon C, Hayes PC. Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection. PLoS One. 2016;11:e0156801. [PMID: 27308823 DOI: 10.1371/journal.pone.0156801] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
13 Zhou C, Wang P, Tu M, Huang Y, Xiong F, Wu Y. Long Non-Coding RNA PART1 Promotes Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cells via miR-149-5p/MAP2K1 Axis. Cancer Manag Res 2020;12:3771-82. [PMID: 32547213 DOI: 10.2147/CMAR.S246311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Patrizi A, Jezequel C, Sulpice L, Meunier B, Rayar M, Boudjema K. Disposable bipolar irrigated sealer (Aquamantys(®)) for liver resection: use with caution. Updates Surg 2016;68:171-7. [PMID: 27193968 DOI: 10.1007/s13304-016-0367-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Dong C, Liu Y, Jiang K, Wang H, Qu W, Zhang C, Liang R, Gao Z, Zhao B, Miao Q, Shao S, Wang L. The Nogo-B receptor promotes human hepatocellular carcinoma cell growth via the Akt signal pathway. J Cell Biochem 2018;119:7738-46. [PMID: 29904947 DOI: 10.1002/jcb.27125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Park JO, Ryoo BY, Yen CJ, Kudo M, Yang L, Abada PB, Cheng R, Orlando M, Zhu AX, Okusaka T. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget. 2016;7:75482-75491. [PMID: 27776351 DOI: 10.18632/oncotarget.12780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
17 Chen D, Liu S, Chen S, Wang Z, Wu Z, Ma K, Fan J, Peng Z. Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation. Int J Clin Oncol 2016;21:1111-9. [PMID: 27368337 DOI: 10.1007/s10147-016-1001-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
18 Kamimura K, Suda T, Yokoo T, Kamimura H, Kanefuji T, Tsuchiya A, Takamura M, Kawai H, Waguri N, Yamagiwa S. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. BMC Cancer. 2017;17:322. [PMID: 28490356 DOI: 10.1186/s12885-017-3320-7.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Zhang F, Zhang S, Sun L, Zhan W, Sun L. Research on registration and navigation technology of augmented reality for ex-vivo hepatectomy. Int J Comput Assist Radiol Surg 2021. [PMID: 34800225 DOI: 10.1007/s11548-021-02531-w] [Reference Citation Analysis]
20 Gao S, Ni Q, Wu X, Cao T. GHR knockdown enhances the sensitivity of HCC cells to sorafenib. Aging (Albany NY) 2020;12:18127-36. [PMID: 32970612 DOI: 10.18632/aging.103625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Kinoshita M, Kanazawa A, Kodai S, Shimizu S, Murata A, Nishio K, Hamano G, Shinkawa H, Tanaka S, Takemura S, Tsukamoto T, Kubo S. Difficulty classifications of laparoscopic repeated liver resection in patients with recurrent hepatocellular carcinoma. Asian J Endosc Surg 2020;13:366-74. [PMID: 31408275 DOI: 10.1111/ases.12746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
22 Feldbrügge L, Wabitsch S, Benzing C, Krenzien F, Kästner A, Haber PK, Atanasov G, Andreou A, Öllinger R, Pratschke J, Schmelzle M. Safety and feasibility of laparoscopic liver resection in patients with a history of abdominal surgeries. HPB (Oxford) 2020;22:1191-6. [PMID: 31831317 DOI: 10.1016/j.hpb.2019.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Villalobos A, Wagstaff W, Guo M, Zhang J, Bercu Z, Whitmore MJ, Cristescu MM, Majdalany BS, Wedd J, Akce M, Magliocca J, Kokabi N. Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:9926704. [PMID: 34336728 DOI: 10.1155/2021/9926704] [Reference Citation Analysis]
24 McKinley SK, Chawla A, Ferrone CR. Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options. Surg Oncol Clin N Am 2019;28:745-62. [PMID: 31472917 DOI: 10.1016/j.soc.2019.06.009] [Reference Citation Analysis]
25 Salazar-Anguiano J, Chávez-López MG, Zúñiga-García V, Camacho J, Elías-Viñas D. Resistive Part of Impedance as a Possible Indicator of Hepatocellular Carcinoma. Arch Med Res 2018;49:89-93. [PMID: 29779755 DOI: 10.1016/j.arcmed.2018.04.012] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 You Y, Wang Z, Ran H, Zheng Y, Wang D, Xu J, Wang Z, Chen Y, Li P. Nanoparticle-enhanced synergistic HIFU ablation and transarterial chemoembolization for efficient cancer therapy. Nanoscale 2016;8:4324-39. [PMID: 26837265 DOI: 10.1039/c5nr08292g] [Cited by in Crossref: 57] [Cited by in F6Publishing: 25] [Article Influence: 9.5] [Reference Citation Analysis]
27 Sun XD, Shi XJ, Chen YG, Wang CL, Ma Q, Lv GY. Elevated Preoperative Neutrophil-Lymphocyte Ratio Is Associated with Poor Prognosis in Hepatocellular Carcinoma Patients Treated with Liver Transplantation: A Meta-Analysis. Gastroenterol Res Pract. 2016;2016:4743808. [PMID: 26843858 DOI: 10.1155/2016/4743808] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
28 Petrizzo A, Caruso FP, Tagliamonte M, Tornesello ML, Ceccarelli M, Costa V, Aprile M, Esposito R, Ciliberto G, Buonaguro FM, Buonaguro L. Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. Sci Rep 2016;6:29258. [PMID: 27387388 DOI: 10.1038/srep29258] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
29 Liang J, Zhu J, Wang M, Singal AG, Odewole M, Kagan S, Renteria V, Liu S, Parikh ND, Lubman DM. Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies. Sci Rep 2019;9:11580. [PMID: 31399619 DOI: 10.1038/s41598-019-48043-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
30 Chen LJ, Chang YJ, Chang YJ. Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma. Oncologist 2021;26:e445-53. [PMID: 32969134 DOI: 10.1002/onco.13535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Qian Y, Wang JW, Fang Y, Yuan XD, Fan YC, Gao S, Wang K. Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma. Med Sci Monit 2020;26:e927444. [PMID: 33320844 DOI: 10.12659/MSM.927444] [Reference Citation Analysis]
32 Dong X, Guo W, Zhang S, Wu T, Sun Z, Yan S, Zheng S. Elevated expression of neuropilin-2 associated with unfavorable prognosis in hepatocellular carcinoma. Onco Targets Ther 2017;10:3827-33. [PMID: 28814881 DOI: 10.2147/OTT.S139044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
33 Wang S, Sun H, Xie Z, Li J, Hong G, Li D, Mallampati S, Zhou X, Zhou C, Zhang H, Cheng Z, Shan H, Ma H. Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983-2012. Oncotarget 2016;7:59820-33. [PMID: 27486977 DOI: 10.18632/oncotarget.10930] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
34 Tian Y, Tang B, Wang C, Sun D, Zhang R, Luo N, Han Z, Liang R, Gao Z, Wang L. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget 2016;7:46230-41. [PMID: 27323827 DOI: 10.18632/oncotarget.10079] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
35 Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016; 8(14): 607-615 [PMID: 27190577 DOI: 10.4254/wjh.v8.i14.607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
36 Miyachi Y, Kaido T, Yao S, Shirai H, Kobayashi A, Hamaguchi Y, Kamo N, Yagi S, Uemoto S. Bone Mineral Density as a Risk Factor for Patients Undergoing Surgery for Hepatocellular Carcinoma. World J Surg 2019;43:920-8. [PMID: 30465085 DOI: 10.1007/s00268-018-4861-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
37 Yin T, Li W, Zhao P, Wang Y, Zheng J. Treatment efficacy of CT-guided percutaneous microwave ablation for primary hepatocellular carcinoma. Clin Radiol 2017;72:136-40. [PMID: 27890422 DOI: 10.1016/j.crad.2016.10.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
38 Ye J, Wu S, Pan S, Huang J, Ge L. Risk scoring based on expression of long non‑coding RNAs can effectively predict survival in hepatocellular carcinoma patients with or without fibrosis. Oncol Rep 2020;43:1451-66. [PMID: 32323856 DOI: 10.3892/or.2020.7528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
39 Long J, Lin J, Wang A, Wu L, Zheng Y, Yang X, Wan X, Xu H, Chen S, Zhao H. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017;10:146. [PMID: 28774337 DOI: 10.1186/s13045-017-0511-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
40 Liu Y, Ren F, Rong M, Luo Y, Dang Y, Chen G. Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues. Cancer Cell Int. 2015;15:62. [PMID: 26109910 DOI: 10.1186/s12935-015-0214-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
41 Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016;64:106-116. [PMID: 26765068 DOI: 10.1002/hep.28453] [Cited by in Crossref: 226] [Cited by in F6Publishing: 208] [Article Influence: 37.7] [Reference Citation Analysis]
42 Kamimura K, Suda T, Yokoo T, Kamimura H, Kanefuji T, Tsuchiya A, Takamura M, Kawai H, Waguri N, Yamagiwa S, Terai S. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. BMC Cancer 2017;17:322. [PMID: 28490356 DOI: 10.1186/s12885-017-3320-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Gao J, Wang SH, Ding XM, Sun WB, Li XL, Xin ZH, Ning CM, Guo SG. Radiofrequency ablation for single hepatocellular carcinoma 3 cm or less as first-line treatment. World J Gastroenterol 2015; 21(17): 5287-5294 [PMID: 25954102 DOI: 10.3748/wjg.v21.i17.5287] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
44 Sharifian M, Baharvand P, Moayyedkazemi A. Liver Cancer: New Insights into Surgical and Nonsurgical Treatments. CCTR 2021;17:197-206. [DOI: 10.2174/1573394717666210219104201] [Reference Citation Analysis]
45 Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One. 2016;11:e0155800. [PMID: 27219517 DOI: 10.1371/journal.pone.0155800] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
46 Ding W, Tan Y, Qian Y, Xue W, Wang Y, Jiang P, Xu X. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials. PLoS One 2020;15:e0229492. [PMID: 32134981 DOI: 10.1371/journal.pone.0229492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Willebrords J, Pereira IV, Maes M, Crespo Yanguas S, Colle I, Van Den Bossche B, Da Silva TC, de Oliveira CP, Andraus W, Alves VA. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res. 2015;59:106-125. [PMID: 26073454 DOI: 10.1016/j.plipres.2015.05.002] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 12.1] [Reference Citation Analysis]
48 Xie L, Li M, Liu D, Wang X, Wang P, Dai H, Yang W, Liu W, Hu X, Zhao M. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway. Molecules 2019;24:E393. [PMID: 30678274 DOI: 10.3390/molecules24030393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
49 Wei X, You X, Zhang J, Zhou C. MicroRNA-1305 Inhibits the Stemness of LCSCs and Tumorigenesis by Repressing the UBE2T-Dependent Akt-Signaling Pathway. Mol Ther Nucleic Acids 2019;16:721-32. [PMID: 31128423 DOI: 10.1016/j.omtn.2019.04.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
50 Schneider C, Johnson SP, Walker-Samuel S, Gurusamy K, Clarkson MJ, Thompson S, Song Y, Totz J, Cook RJ, Desjardins AE, Hawkes DJ, Davidson BR. Utilizing confocal laser endomicroscopy for evaluating the adequacy of laparoscopic liver ablation. Lasers Surg Med 2016;48:299-310. [PMID: 26718623 DOI: 10.1002/lsm.22464] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
51 Ting CT, Kuo CJ, Hu HY, Lee YL, Tsai TH. Prescription frequency and patterns of Chinese herbal medicine for liver cancer patients in Taiwan: a cross-sectional analysis of the National Health Insurance Research Database. BMC Complement Altern Med 2017;17:118. [PMID: 28219357 DOI: 10.1186/s12906-017-1628-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
52 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 17.7] [Reference Citation Analysis]
53 Buonaguro L, Tagliamonte M, Petrizzo A, Damiano E, Tornesello ML, Buonaguro FM. Cellular prognostic markers in hepatocellular carcinoma. Future Oncol 2015;11:1591-8. [PMID: 26043213 DOI: 10.2217/fon.15.39] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
54 Gu J, Zhang X, Miao R, Ma X, Xiang X, Fu Y, Liu C, Niu W, Qu K. A three-long non-coding RNA-expression-based risk score system can better predict both overall and recurrence-free survival in patients with small hepatocellular carcinoma. Aging (Albany NY). 2018;10:1627-1639. [PMID: 30018179 DOI: 10.18632/aging.101497] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
55 Wang ZD, Qu FY, Chen YY, Ran ZS, Liu HY, Zhang HD. Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. J Zhejiang Univ Sci B 2017;18:27-36. [PMID: 28070994 DOI: 10.1631/jzus.B1600205] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
56 Jiang W, Li T, Guo J, Wang J, Jia L, Shi X, Yang T, Jiao R, Wei X, Feng Z, Tang Q, Ji G. Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Front Oncol 2021;11:546586. [PMID: 33777728 DOI: 10.3389/fonc.2021.546586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Shang M, Xu X, Zhang M, Yang H. Long non-coding RNA linc-ITGB1 promotes cell proliferation and migration in human hepatocellular carcinoma cells. Exp Ther Med 2017;14:4687-92. [PMID: 29201168 DOI: 10.3892/etm.2017.5143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
58 Zhang Q, Yuan XF, Lu Y, Li ZZ, Bao SQ, Zhang XL, Yang YY, Fan DM, Zhang YZ, Wu CX, Guo HX, Zhang YJ, Ye Z, Xiong DS. Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells. Int J Cancer 2017;141:1445-57. [PMID: 28643325 DOI: 10.1002/ijc.30846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
59 Duan Y, Li J, Jing X, Ding X, Yu Y, Zhao Q. Fucoidan Induces Apoptosis and Inhibits Proliferation of Hepatocellular Carcinoma via the p38 MAPK/ERK and PI3K/Akt Signal Pathways. Cancer Manag Res 2020;12:1713-23. [PMID: 32210612 DOI: 10.2147/CMAR.S243495] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
60 Wang CY, Xia JG, Yang ZQ, Zhou WZ, Chen WH, Qi CJ, Gu JP, Wang Q. Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma. Sci Rep 2020;10:4434. [PMID: 32157110 DOI: 10.1038/s41598-020-61209-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
61 Kanthaje S, Makol A, Chakraborti A. Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks. Hepatol Res 2018;48:5-14. [PMID: 29055114 DOI: 10.1111/hepr.12991] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
62 Ludwig JM, Zhang D, Xing M, Kim HS. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. Eur Radiol 2017;27:2031-41. [PMID: 27562480 DOI: 10.1007/s00330-016-4548-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
63 Nishi M, Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Hemobilia immediately after transcatheter arterial chemoembolization using drug-eluting beads for hepatocellular carcinoma with intrahepatic bile duct invasion. Hepatol Res 2018;48:329-32. [PMID: 29098752 DOI: 10.1111/hepr.12995] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
64 Kim IG, Hu XG, Wang HJ, Kim BW, Hong SY, Shen XY. The 7th/8th American Joint Committee on Cancer and the Modified Union for International Cancer Control Staging System for Hepatocellular Carcinoma. Yonsei Med J 2019;60:140-7. [PMID: 30666835 DOI: 10.3349/ymj.2019.60.2.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
65 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol 2015; 7(15): 1913-1920 [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
66 Cabibbo G, Reig M, Gadaleta-caldarola G, Galati G, Lombardi G, Mazza G, Marzi L, Saitta C, Nault J, Sacco R. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1. Future Oncology 2016;12:281-4. [DOI: 10.2217/fon.15.323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
67 Pelosof L, Lemery S, Casak S, Jiang X, Rodriguez L, Pierre V, Bi Y, Liu J, Zirkelbach JF, Patel A, Goldberg KB, McKee AE, Keegan P, Pazdur R. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib. Oncologist 2018;23:496-500. [PMID: 29386313 DOI: 10.1634/theoncologist.2017-0422] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
68 Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Hepatocell Carcinoma 2021;8:1233-40. [PMID: 34676181 DOI: 10.2147/JHC.S332420] [Reference Citation Analysis]
69 Lu Q, Li J, Cao H, Lv C, Wang X, Cao S. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep 2020;40:BSR20192424. [PMID: 32039435 DOI: 10.1042/BSR20192424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
70 Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015; 7(3): 566-574 [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
71 Yu MC, Lee CW, Lin CH, Wu CH, Lee YS, Tsai CL, Tsai CN. Differential hypermethylation of the VTRNA2-1 promoter in hepatocellular carcinoma as a prognostic factor: Tumor marker prognostic study. Int J Surg 2020;79:282-9. [PMID: 32417463 DOI: 10.1016/j.ijsu.2020.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
72 Dou JP, Yu J, Han ZY, Liu FY, Cheng ZG, Liang P. Microwave ablation for hepatocellular carcinoma associated with Budd-Chiari syndrome after transarterial chemoembolization: an analysis of ten cases. Abdom Radiol (NY) 2017;42:962-8. [PMID: 27688061 DOI: 10.1007/s00261-016-0923-4] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
73 Wang YG, Zheng DH, Shi M, Xu XM. T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. J Med Genet 2019;56:22-8. [PMID: 30518547 DOI: 10.1136/jmedgenet-2018-105570] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
74 Higaki E, Fukaya M, Miyata K, Kawai R, Abe T. Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma. Surg Case Rep 2020;6:138. [PMID: 32548687 DOI: 10.1186/s40792-020-00902-0] [Reference Citation Analysis]
75 Kantor O, Baker MS. Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. Cancer Treat Res 2016;168:165-83. [PMID: 29206369 DOI: 10.1007/978-3-319-34244-3_8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
76 Li W, Wang Y, Gao W, Zheng J. Combination of transcatheter arterial chemoembolization and CT-guided percutaneous segment ablation for hepatocellular carcinoma therapy: A retrospective study. Medicine (Baltimore) 2016;95:e5422. [PMID: 27893681 DOI: 10.1097/MD.0000000000005422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Lin T, Gu J, Qu K, Zhang X, Ma X, Miao R, Xiang X, Fu Y, Niu W, She J, Liu C. A new risk score based on twelve hepatocellular carcinoma-specific gene expression can predict the patients' prognosis. Aging (Albany NY) 2018;10:2480-97. [PMID: 30243023 DOI: 10.18632/aging.101563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
78 Xia W, Ni J, Zhuang J, Qian L, Wang P, Wang J. MiR-103 regulates hepatocellular carcinoma growth by targeting AKAP12. The International Journal of Biochemistry & Cell Biology 2016;71:1-11. [DOI: 10.1016/j.biocel.2015.11.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
79 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Itobayashi E, Nouso K, Kariyama K, Ishikawa T, Hirooka M, Hiasa Y. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. Cancer Sci. 2017;108:1414-1420. [PMID: 28406546 DOI: 10.1111/cas.13257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
80 Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infect Agent Cancer 2018;13:10. [PMID: 29599818 DOI: 10.1186/s13027-018-0183-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
81 Peng J, Li JJ, Li J, Li HW, Xu GP, Jia RR, Zhang XN, Zhao Y. Could ADC values be a promising diagnostic criterion for differentiating malignant and benign hepatic lesions in Asian populations: A meta-analysis. Medicine (Baltimore) 2016;95:e5470. [PMID: 27902599 DOI: 10.1097/MD.0000000000005470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
82 Buonaguro L; HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunol Immunother 2016;65:93-9. [PMID: 26093657 DOI: 10.1007/s00262-015-1728-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
83 Zhou L, Ji F, Zhang T, Wang F, Li Y, Yu Z, Jin X, Ruan B. An fluorescent aptasensor for sensitive detection of tumor marker based on the FRET of a sandwich structured QDs-AFP-AuNPs. Talanta 2019;197:444-50. [PMID: 30771960 DOI: 10.1016/j.talanta.2019.01.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
84 Sun L, Su Y, Liu X, Xu M, Chen X, Zhu Y, Guo Z, Bai T, Dong L, Wei C, Cai X, He B, Pan Y, Sun H, Wang S. Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma. J Cancer. 2018;9:2631-2639. [PMID: 30087703 DOI: 10.7150/jca.24978] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 13.3] [Reference Citation Analysis]
85 Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol 2016; 22(4): 1497-1512 [PMID: 26819517 DOI: 10.3748/wjg.v22.i4.1497] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
86 Deng Y, Zhang F, Sun ZG, Wang S. Development and Validation of a Prognostic Signature Associated With Tumor Microenvironment Based on Autophagy-Related lncRNA Analysis in Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:762570. [PMID: 34970559 DOI: 10.3389/fmed.2021.762570] [Reference Citation Analysis]
87 Xu W, Guo W, Lu P, Ma D, Liu L, Yu F. Identification of an autophagy-related gene signature predicting overall survival for hepatocellular carcinoma. Biosci Rep 2021;41:BSR20203231. [PMID: 33351066 DOI: 10.1042/BSR20203231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Jin H, Wang H, Li G, Hou Q, Wu W, Liu F. Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma. J Int Med Res 2020;48:300060520961260. [PMID: 33044114 DOI: 10.1177/0300060520961260] [Reference Citation Analysis]
89 Egeland C, Rostved AA, Schultz NA, Pommergaard HC, Daugaard TR, Thøfner LB, Rasmussen A, Hillingsø JG. Morbidity and mortality after liver surgery for colorectal liver metastases: a cohort study in a high-volume fast-track programme. BMC Surg 2021;21:312. [PMID: 34261457 DOI: 10.1186/s12893-021-01301-4] [Reference Citation Analysis]
90 Nicolè L, Sanavia T, Cappellesso R, Maffeis V, Akiba J, Kawahara A, Naito Y, Radu CM, Simioni P, Serafin D, Cortese G, Guido M, Zanus G, Yano H, Fassina A. Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3+ and CD8+ T cell density and predict prognosis in hepatocellular carcinoma. J Immunother Cancer 2022;10:e004031. [PMID: 35264437 DOI: 10.1136/jitc-2021-004031] [Reference Citation Analysis]
91 Yang J, Xu QC, Wang ZY, Lu X, Pan LK, Wu J, Wang C. Integrated Analysis of an lncRNA-Associated ceRNA Network Reveals Potential Biomarkers for Hepatocellular Carcinoma. J Comput Biol 2021;28:330-44. [PMID: 33185458 DOI: 10.1089/cmb.2019.0250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Wen X, Yao M, Lu Y, Chen J, Zhou J, Chen X, Zhang Y, Lu W, Qian X, Zhao J, Zhang L, Ding S, Lu F. Integration of Prealbumin into Child-Pugh Classification Improves Prognosis Predicting Accuracy in HCC Patients Considering Curative Surgery. J Clin Transl Hepatol. 2018;6:377-384. [PMID: 30637214 DOI: 10.14218/jcth.2018.00004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
93 Tsang CM, Cheung KC, Cheung YC, Man K, Lui VW, Tsao SW, Feng Y. Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochim Biophys Acta. 2015;1852:541-551. [PMID: 25496992 DOI: 10.1016/j.bbadis.2014.12.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
94 Gon H, Komatsu S, Murakami S, Kido M, Tanaka M, Kuramitsu K, Tsugawa D, Awazu M, Toyama H, Fukumoto T. Real-time navigation during hepatectomy using fusion indocyanine green-fluorescence imaging: protocol for a prospective cohort study. BMJ Open 2019;9:e030233. [PMID: 31427337 DOI: 10.1136/bmjopen-2019-030233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
95 Gwiasda J, Schulte A, Kaltenborn A, Ramackers W, Kleine M, Beetz O, Klempnauer J, Emmanouilidis N, Schrem H. Identification of the resection severity index as a significant independent prognostic factor for early mortality and observed survival >5 and >10 years after liver resection for hepatocellular carcinoma. Surg Oncol 2017;26:178-87. [PMID: 28577724 DOI: 10.1016/j.suronc.2017.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
96 Purnamasari R, Winarni D, Permanasari AA, Agustina E, Hayaza S, Darmanto W. Anticancer Activity of Methanol Extract of Ficus carica Leaves and Fruits Against Proliferation, Apoptosis, and Necrosis in Huh7it Cells. Cancer Inform 2019;18:1176935119842576. [PMID: 31037025 DOI: 10.1177/1176935119842576] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
97 Han D, Yang P, Qin B, Ji G, Wu Y, Yu L, Zhang H. Upregulation of Nogo-B by hypoxia inducible factor-1 and activator protein-1 in hepatocellular carcinoma. Cancer Sci 2021;112:2728-38. [PMID: 33963651 DOI: 10.1111/cas.14941] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res 2017;27:59-73. [PMID: 28008927 DOI: 10.1038/cr.2016.153] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
99 Lencioni R, Crocetti L, Narayanan G. Irreversible Electroporation in the Treatment of Hepatocellular Carcinoma. Techniques in Vascular and Interventional Radiology 2015;18:135-9. [DOI: 10.1053/j.tvir.2015.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
100 Zhao J, Chen HQ, Yang HF, Li XY, Liu WB. Gene expression network related to DNA methylation and miRNA regulation during the process of aflatoxin B1-induced malignant transformation of L02 cells. J Appl Toxicol 2021. [PMID: 34561900 DOI: 10.1002/jat.4233] [Reference Citation Analysis]
101 Al-Alem F, Mattar RE, Fadl OA, Alsharabi A, Al-Saif F, Hassanain M. Morbidity and mortality and predictors of outcome following hepatectomy at a Saudi tertiary care center. Ann Saudi Med 2016;36:414-21. [PMID: 27920414 DOI: 10.5144/0256-4947.2016.414] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
102 Ishii M, Mizuguchi T, Harada K, Ota S, Meguro M, Ueki T, Nishidate T, Okita K, Hirata K. Comprehensive review of post-liver resection surgical complications and a new universal classification and grading system. World J Hepatol 2014; 6(10): 745-751 [PMID: 25349645 DOI: 10.4254/wjh.v6.i10.745] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
103 Ertel AE, Shah SA. Surgical Approaches to Hepatocellular Carcinoma. Semin Roentgenol 2016;51:88-94. [PMID: 27105963 DOI: 10.1053/j.ro.2016.02.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Wu F, Chen WJ, Yan L, Tan GQ, Li WT, Zhu XJ, Ge XC, Liu JW, Wang BL. Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathway. Cancer Med 2016;5:370-85. [PMID: 26714930 DOI: 10.1002/cam4.588] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
105 Yang Y, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med 2018;15:299-310. [PMID: 30197797 DOI: 10.20892/j.issn.2095-3941.2017.0177] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
106 Jiang T, Huang Z, Zhang S, Zou W, Xiang L, Wu X, Shen Y, Liu W, Zeng Z, Zhao A, Zhou S, Zeng Q. miR‑23b inhibits proliferation of SMMC‑7721 cells by directly targeting IL‑11. Mol Med Rep 2018;18:1591-9. [PMID: 29901200 DOI: 10.3892/mmr.2018.9151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Yu MC, Lee CW, Lee YS, Lian JH, Tsai CL, Liu YP, Wu CH, Tsai CN. Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data. World J Gastroenterol 2017; 23(44): 7818-7829 [PMID: 29209123 DOI: 10.3748/wjg.v23.i44.7818] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
108 Tsai CN, Yu SC, Lee CW, Pang JS, Wu CH, Lin SE, Chung YH, Tsai CL, Hsieh SY, Yu MC. SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo. Oncogene 2020;39:4695-710. [PMID: 32404985 DOI: 10.1038/s41388-020-1319-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
109 Coon C, Berger N, Eastwood D, Tsai S, Christians K, Mogal H, Clarke C, Gamblin TC. Primary Liver Cancer: An NCDB Analysis of Overall Survival and Margins After Hepatectomy. Ann Surg Oncol 2020;27:1156-63. [DOI: 10.1245/s10434-019-07843-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
110 Shi Y, Qin N, Zhou Q, Chen Y, Huang S, Chen B, Shen G, Jia H. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma. J Transl Med 2017;15:176. [PMID: 28810875 DOI: 10.1186/s12967-017-1275-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
111 Azumi M, Suda T, Terai S, Akazawa K. Prognostic Impact of Indocyanine Green Plasma Disappearance Rate in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: A Prognostic Nomogram Study. Intern Med 2017;56:1001-7. [PMID: 28458303 DOI: 10.2169/internalmedicine.56.7278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
112 Li X, Qian X, Peng LX, Jiang Y, Hawke DH, Zheng Y, Xia Y, Lee JH, Cote G, Wang H, Wang L, Qian CN, Lu Z. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat Cell Biol 2016;18:561-71. [PMID: 27088854 DOI: 10.1038/ncb3338] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 14.0] [Reference Citation Analysis]
113 Chen X, Wang L, Zhao Y, Yuan S, Wu Q, Zhu X, Niang B, Wang S, Zhang J. ST6Gal-I modulates docetaxel sensitivity in human hepatocarcinoma cells via the p38 MAPK/caspase pathway. Oncotarget 2016;7:51955-64. [PMID: 27340870 DOI: 10.18632/oncotarget.10192] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
114 Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cell Mol Life Sci 2019;76:4869-86. [PMID: 31377844 DOI: 10.1007/s00018-019-03255-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
115 Liu Z, Wang Q, Mao J, Wang K, Fang Z, Miao QR, Ye M. Comparative proteomic analysis of protein methylation provides insight into the resistance of hepatocellular carcinoma to 5-fluorouracil. J Proteomics 2020;219:103738. [PMID: 32198070 DOI: 10.1016/j.jprot.2020.103738] [Reference Citation Analysis]
116 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
117 Luo D, Li H, Hu J, Zhang M, Zhang S, Wu L, Han B. Development and Validation of Nomograms Based on Gamma-Glutamyl Transpeptidase to Platelet Ratio for Hepatocellular Carcinoma Patients Reveal Novel Prognostic Value and the Ratio Is Negatively Correlated With P38MAPK Expression. Front Oncol 2020;10:548744. [PMID: 33344225 DOI: 10.3389/fonc.2020.548744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Kong L, Zhou Y, Bu H, Lv T, Shi Y, Yang J. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res 2016;35:131. [PMID: 27589954 DOI: 10.1186/s13046-016-0412-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 8.8] [Reference Citation Analysis]
119 Li JJ, Luo J, Lu JN, Liang XN, Luo YH, Liu YR, Yang J, Ding H, Qin GH, Yang LH, Dang YW, Yang H, Chen G. Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study. Cancer Cell Int 2016;16:76. [PMID: 27708550 DOI: 10.1186/s12935-016-0352-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
120 Boyle DA. Hepatocellular Carcinoma: Implications for Asia-Pacific Oncology Nurses. Asia Pac J Oncol Nurs 2017;4:98-103. [PMID: 28503639 DOI: 10.4103/2347-5625.204497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
121 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
122 Ke M, Dong J, Wang Y, Zhang J, Zhang M, Wu Z, Lv Y, Wu R. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells. The International Journal of Biochemistry & Cell Biology 2018;101:39-48. [DOI: 10.1016/j.biocel.2018.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
123 Khandoga A, Drefs M, Schoenberg M, Schiergens T, Frenes K, Op den Winkel M, Trumm C, Angele MK, Guba M, Werner J, Rentsch M. Differential significance of early surgical complications for acute and long-term recurrence-free survival following surgical resection of hepatocellular carcinoma: do comorbidities play a role? Eur J Gastroenterol Hepatol 2017;29:1045-53. [PMID: 28562395 DOI: 10.1097/MEG.0000000000000912] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
124 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 164] [Article Influence: 27.8] [Reference Citation Analysis]
125 Fiorentini G, Sarti D, Carandina R, Mulazzani L, Mincarelli C, Candelari R, Argirò R, Fiorentini C, Aliberti C. A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma. Future Oncology 2019;15:695-703. [DOI: 10.2217/fon-2018-0425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
126 Kinoshita M, Kanazawa A, Tanaka S, Takemura S, Amano R, Kimura K, Shinkawa H, Ohira G, Nishio K, Kubo S. Indications of Laparoscopic Repeat Liver Resection for Recurrent Hepatocellular Carcinoma. Annals of Gastroent Surgery 2022;6:119-26. [DOI: 10.1002/ags3.12493] [Reference Citation Analysis]
127 Du L, Wang L, Yang H, Duan J, Lai J, Wu W, Fan S, Zhi X. Sex Comb on Midleg Like-2 Accelerates Hepatocellular Carcinoma Cell Proliferation and Metastasis by Activating Wnt/β-Catenin/EMT Signaling. Yonsei Med J 2021;62:1073-82. [PMID: 34816637 DOI: 10.3349/ymj.2021.62.12.1073] [Reference Citation Analysis]
128 Yang DL, Zhang YJ, He LJ, Hu CS, Gao LX, Huang JH, Tang Y, Luo J, Tang DY, Chen ZZ. Demethylzeylasteral (T-96) initiates extrinsic apoptosis against prostate cancer cells by inducing ROS-mediated ER stress and suppressing autophagic flux. Biol Res 2021;54:27. [PMID: 34488902 DOI: 10.1186/s40659-021-00350-6] [Reference Citation Analysis]
129 Zhang Y, Liu P, Jiang Y, Dou X, Yan J, Ma C, Fan Q, Wang W, Su F, Tang H, Su X. High Expression of Neuropilin-1 Associates with Unfavorable Clinicopathological Features in Hepatocellular Carcinoma. Pathol Oncol Res 2016;22:367-75. [PMID: 26563279 DOI: 10.1007/s12253-015-0003-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
130 Gu X, Fu M, Ding Y, Ni H, Zhang W, Zhu Y, Tang X, Xiong L, Li J, Qiu L, Xu J, Zhu J. TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC. PLoS One 2014;9:e106161. [PMID: 25171061 DOI: 10.1371/journal.pone.0106161] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
131 Miszczuk MA, Chapiro J, Geschwind JH, Thakur V, Nezami N, Laage-Gaupp F, Kulon M, van Breugel JMM, Fereydooni A, Lin M, Savic LJ, Tegel B, Wahlin T, Funai E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Transl Oncol 2020;13:100742. [PMID: 32092672 DOI: 10.1016/j.tranon.2020.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
132 Ma XL, Zhou JY, Gao XH, Tian L, Wu J, Zhang CY, Zhou Y, Dai Q, Wang BL, Pan BS, Yang XR, Guo W. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clin Chim Acta. 2016;462:15-22. [PMID: 27520748 DOI: 10.1016/j.cca.2016.08.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
133 Seror O, N'Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M, Trinchet JC, Diallo A, Sellier N. Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results. Radiology 2016;280:611-21. [PMID: 27010381 DOI: 10.1148/radiol.2016150743] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 8.5] [Reference Citation Analysis]
134 Kim BR, Lee JM, Lee DH, Yoon JH, Hur BY, Suh KS, Yi NJ, Lee KB, Han JK. Diagnostic Performance of Gadoxetic Acid-enhanced Liver MR Imaging versus Multidetector CT in the Detection of Dysplastic Nodules and Early Hepatocellular Carcinoma. Radiology. 2017;285:134-146. [PMID: 28609205 DOI: 10.1148/radiol.2017162080] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
135 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 12.1] [Reference Citation Analysis]
136 Das JP, Thulasidasan N, Ahmed I, Diamantopoulos A. Transarterial chemoembolization for hepatocellular carcinoma: a bibliometric analysis of the most cited articles. Jpn J Radiol 2020;38:1190-6. [PMID: 32767200 DOI: 10.1007/s11604-020-01028-x] [Reference Citation Analysis]
137 Chang L, Hou Y, Zhu L, Wang Z, Chen G, Shu C, Liu Y. Veliparib overcomes multidrug resistance in liver cancer cells. Biochem Biophys Res Commun 2020;521:596-602. [PMID: 31679697 DOI: 10.1016/j.bbrc.2019.10.141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Fong ZV, Tanabe KK. ASO Author Reflections: Variations and Inconsistencies in the Guidelines for the Clinical Management of Cholangiocarcinoma. Ann Surg Oncol 2021. [PMID: 33677763 DOI: 10.1245/s10434-021-09703-7] [Reference Citation Analysis]
139 Ye J, Zhang J, Lv Y, Wei J, Shen X, Huang J, Wu S, Luo X. Integrated analysis of a competing endogenous RNA network reveals key long noncoding RNAs as potential prognostic biomarkers for hepatocellular carcinoma. J Cell Biochem. 2019;120:13810-13825. [PMID: 30989713 DOI: 10.1002/jcb.28655] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
140 Bae SH, Kim MS, Jang WI, Kay CS, Kim W, Kim ES, Kim JH, Kim JH, Yang KM, Lee KC. Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group. Jpn J Clin Oncol. 2016;46:363-369. [PMID: 26826720 DOI: 10.1093/jjco/hyv209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
141 Méndez Romero A, de Man RA. Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care. Best Pract Res Clin Gastroenterol 2016;30:603-16. [PMID: 27644908 DOI: 10.1016/j.bpg.2016.06.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
142 Freeman E, Cheung W, Kavnoudias H, Majeed A, Kemp W, Roberts SK. Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre. Cardiovasc Intervent Radiol 2021;44:247-53. [PMID: 33051707 DOI: 10.1007/s00270-020-02666-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
143 Petrizzo A, Buonaguro L. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. J Immunother Cancer. 2016;4:71. [PMID: 27879973 DOI: 10.1186/s40425-016-0182-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
144 Lai Y, Feng B, Abudoureyimu M, Zhi Y, Zhou H, Wang T, Chu X, Chen P, Wang R. Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma. Front Oncol 2019;9:1156. [PMID: 31750247 DOI: 10.3389/fonc.2019.01156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
145 Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019;14:437-45. [DOI: 10.1016/j.cpet.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol. 2016;3:57-59. [PMID: 26998221 DOI: 10.2217/hep.15.41] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 9.5] [Reference Citation Analysis]
147 Wang J, Tan Q, Wang W, Yu J. Mechanism of the Regulatory Effect of Overexpression of circMTO1 on Proliferation and Apoptosis of Hepatoma Cells via miR-9-5p/NOX4 Axis. Cancer Manag Res 2020;12:3915-25. [PMID: 32547227 DOI: 10.2147/CMAR.S240719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
148 Zhou Y, Li Y, Xu S, Lu J, Zhu Z, Chen S, Tan Y, He P, Xu J, Proud CG, Xie J, Shen K. Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3. Int J Cancer 2020;146:1383-95. [PMID: 31286509 DOI: 10.1002/ijc.32560] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
149 Xie YX, Liao R, Pan L, Du CY. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma. Immunol Lett 2017;188:116-23. [PMID: 28668554 DOI: 10.1016/j.imlet.2017.06.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
150 Park SJ, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kang HJ, Yoon JH, Lee DH, Kim SH, Lee JY, Lee JM. Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. Liver Cancer 2021;10:72-81. [PMID: 33708641 DOI: 10.1159/000512338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Ma W, Chen X, Yuan Y. T-cell-associated immunotherapy: a promising strategy for the treatment of hepatocellular carcinoma. Immunotherapy 2017;9:523-5. [PMID: 28595519 DOI: 10.2217/imt-2017-0053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
152 Gao T, Zhi J, Mu C, Gu S, Xiao J, Yang J, Wang Z, Xiang Y. One-step detection for two serological biomarker species to improve the diagnostic accuracy of hepatocellular carcinoma. Talanta 2018;178:89-93. [DOI: 10.1016/j.talanta.2017.09.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
153 Prachayakul V, Aswakul P. Spontaneous hepaticoduodenal and choledochoduodenal fistula mimicking duodenal ulcer perforation, a very rare complication of transarterial chemoembolization. Case Rep Gastroenterol 2015;9:68-73. [PMID: 25873850 DOI: 10.1159/000369248] [Reference Citation Analysis]
154 Noda T, Eguchi H, Wada H, Iwagami Y, Yamada D, Asaoka T, Gotoh K, Kawamoto K, Takeda Y, Tanemura M. Short-term surgical outcomes of minimally invasive repeat hepatectomy for recurrent liver cancer. Surg Endosc. 2018;32:46-52. [PMID: 28639044 DOI: 10.1007/s00464-017-5632-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
155 Tagliamonte M, Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Buonaguro L. Potentiating cancer vaccine efficacy in liver cancer. Oncoimmunology 2018;7:e1488564. [PMID: 30288355 DOI: 10.1080/2162402X.2018.1488564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
156 Zhang M, Liu S, Chua MS, Li H, Luo D, Wang S, Zhang S, Han B, Sun C. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway. Cell Death Dis 2019;10:612. [PMID: 31406106 DOI: 10.1038/s41419-019-1856-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
157 Pang YB, He J, Cui BY, Xu S, Li XL, Wu MY, Liang R, Feng Y, Guo X, Zhang XH, Luo XL. A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma. Stem Cells Int 2019;2019:5680327. [PMID: 31065274 DOI: 10.1155/2019/5680327] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
158 Breen DJ, Lencioni R. Image-guided ablation of primary liver and renal tumours. Nat Rev Clin Oncol. 2015;12:175-186. [PMID: 25601446 DOI: 10.1038/nrclinonc.2014.237] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
159 Liang H, Xu M, Xiong Z, Hu K, Yang J, Cao M, Zhong Z, Yao Z, Deng M, Liu B. Identification of miRNAs as diagnostic and prognostic markers in hepatocellular carcinoma. Aging (Albany NY) 2021;13:6115-33. [PMID: 33617479 DOI: 10.18632/aging.202606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
160 Xuan Z, Wu N, Li C, Liu Y. Application of contrast-enhanced ultrasound in the pathological grading and prognosis prediction of hepatocellular carcinoma. Transl Cancer Res 2021;10:4106-15. [PMID: 35116708 DOI: 10.21037/tcr-21-1264] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
162 Ratti F, Barkhatov LI, Tomassini F, Cipriani F, Kazaryan AM, Edwin B, Abu Hilal M, Troisi RI, Aldrighetti L. Learning curve of self-taught laparoscopic liver surgeons in left lateral sectionectomy: results from an international multi-institutional analysis on 245 cases. Surg Endosc 2016;30:3618-29. [PMID: 26572765 DOI: 10.1007/s00464-015-4665-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
163 Ji Y, Chen H, Gow W, Ma L, Jin Y, Hui B, Yang Z, Wang Z. Potential biomarkers Ang II/AT1R and S1P/S1PR1 predict the prognosis of hepatocellular carcinoma. Oncol Lett 2020;20:208. [PMID: 32963614 DOI: 10.3892/ol.2020.12071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
164 Wang Z, Chu H, Yang K, Zhao B, Liang Z, Zhang L, Zhang Y. Label-Free Quantitative Proteomics Analysis of the Sorafenib Resistance in HepG2 Cells. J Anal Test . [DOI: 10.1007/s41664-021-00176-x] [Reference Citation Analysis]
165 Buonaguro L; HEPAVAC Consortium. New vaccination strategies in liver cancer. Cytokine Growth Factor Rev 2017;36:125-9. [PMID: 28688773 DOI: 10.1016/j.cytogfr.2017.06.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
166 Savic LJ, Schobert IT, Peters D, Walsh JJ, Laage-Gaupp FM, Hamm CA, Tritz N, Doemel LA, Lin M, Sinusas A, Schlachter T, Duncan JS, Hyder F, Coman D, Chapiro J. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment. Clin Cancer Res 2020;26:428-38. [PMID: 31582517 DOI: 10.1158/1078-0432.CCR-19-1702] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
167 Liu Z, Wang Y, Yao Y, Fang Z, Miao QR, Ye M. Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. J Proteomics 2019;208:103501. [PMID: 31454556 DOI: 10.1016/j.jprot.2019.103501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
168 Gao J, Zhang Q, Zhang J, Kong J, Wang S, Ding X, Ke S, Sun W. Radiofrequency Ablation of the Main Lesion of Hepatocellular Carcinoma and Bile Duct Tumor Thrombus as a Radical Therapeutic Alternative: Two Case Reports. Medicine (Baltimore) 2015;94:e1122. [PMID: 26166111 DOI: 10.1097/MD.0000000000001122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]